Drug Approval | August 20, 2022
DCGI approves AstraZeneca 's Olaparib film-coated tablets
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
OrderPoint was designed as an advanced DTR solution from its first release in 2016.
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
The Supervisory Board has unanimously decided to propose Roy Jakobs as the next President and CEO of Royal Philips to its General Meeting of Shareholders.
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
Man lost 54 Kgs in 6 months with MGB procedure
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Subscribe To Our Newsletter & Stay Updated
